Testimony to Congress
The testimony of NIDA Director, Nora D. Volkow, M.D., and other senior staff before congress.
Hearing on Cannabis Policies for the New Decade
Chairwoman Eshoo, Ranking Member Burgess, and members of the Subcommittee, thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH)...
|
Marijuana and America’s Health: Questions and Issues for Policy Makers
Go to the Senate Caucus on International Narcotics Control site Chairman Cornyn, Co-Chairwoman Feinstein and members of the Caucus on International Narcotics Control, we appreciate the opportunity to share the...
|
Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives
Testimony by Dr. Nora Volkow, NIDA Director and others to the House Committee on Energy and Commerce
|
The Federal Response to the Opioid Crisis
Testimony by Dr. Francis Collins, NIH Director and others before the Senate Committee on Health, Education, Labor & Pensions
|
Research on the Use and Misuse of Fentanyl and Other Synthetic Opioids
Testimony by Wilson M. Compton, M.D., Deputy Director, National Institute on Drug Abuse before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations
|
Fiscal Year 2017 Budget Request
Testimony by Nora D. Volkow, M.D., Director, National Institute on Drug Abuse, before the House Subcommittee on Labor-HHS-Education Appropriations
|
Researching the Potential Medical Benefits and Risks of Marijuana
Testimony by Susan R.B. Weiss, Ph.D. - Director, Division of Extramural Research, National Institute on Drug Abuse, before the Senate Judiciary Committee, Subcommittee on Crime and Terrorism
|
What Science tells us About Opioid Abuse and Addiction
Testimony by Nora D. Volkow, M.D., Director, National Institute on Drug Abuse, before the Senate Judiciary Committee
|